A. N. Hata

This study constructs a multi-omic atlas of TP53-mutant lung adenocarcinoma tumors, revealing altered cellular identity, gene expression programs, and spatial interactions in the tumor microenvironment.

The paper identifies targeted therapies that enhance lung cancer vulnerability to macrophage attack when combined with anti-CD47 antibodies, showing synergy across multiple genetic mutations.

This study shows LKB1 suppresses JNK-dependent stress signaling in KRAS-mutant lung cancers, revealing a therapy-induced vulnerability that could improve KRAS-targeted therapies.

This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.

Stitchr generates full-length coding TCR sequences from V/J/CDR3 information, validated through synthesis and transduction in Jurkat cells, enabling efficient TCR engineering and analysis.

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

The paper develops a bio-mathematical model to simulate recurrence patterns in lung cancer under combined targeted therapy and CRT, showing that long induction periods may reduce the effectiveness of adjuvant therapy.